Key Market Indicators
The market for blood and blood forming organs medicines in Austria is expected to reach $489.8 million by 2026. This growth is based on a year-on-year compound annual growth rate (CAGR) of 2.2%, beginning from 2021 when the market was worth $425.3 million. Since 2015, Austrian market growth has averaged 6.5% per year. Austria currently sits in 14th place in the world rankings, while the Czech Republic leads the way with $425.3 million. Germany, Italy, and South Korea take the next three spots. The prevalence of anemia in Austria is predicted to reach 12,220 hospital discharges by 2026. This is a 0.9% average year-on-year increase from 11,520 hospital discharges in 2021. Since 1994, Austrian demand for anemia treatments has risen by 0.9% annually. Currently, Austria is in 15th place globally, while Belgium is in the top spot with 11,520 hospital discharges. Germany, the UK, and Poland take the next three spots.
